Sarepta Therapeutics, Inc. Forecast, price target & analysts
Sarepta Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Sarepta Therapeutics, Inc. Classifications & Recommendation:
Sarepta Therapeutics, Inc. Price Target
| Target Price | $180.62 |
| Price | $103.06 |
| Potential |
75.26%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .
The average Sarepta Therapeutics, Inc. target price is $180.62.
This is
75.26%
register free of charge
$215.00
108.62%
register free of charge
$75.00
27.23%
register free of charge
|
|
| A rating was issued by 23 analysts: 21 Analysts recommend Sarepta Therapeutics, Inc. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of
75.26%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.90 | 3.11 |
| 52.97% | 63.27% | |
| EBITDA Margin | 13.32% | 36.51% |
| 179.28% | 174.04% | |
| Net Margin | 11.92% | 33.67% |
| 126.37% | 182.43% |
20 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Sarepta Therapeutics, Inc. EBITDA forecast 2025. The average Sarepta Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Sarepta Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sarepta Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.34 | 10.79 |
| 140.34% | 361.11% | |
| P/E | 9.55 | |
| EV/Sales | 3.16 |
13 Analysts have issued a Sarepta Therapeutics, Inc. forecast for earnings per share. The average Sarepta Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Sarepta Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sarepta Therapeutics, Inc....
Current Sarepta Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 27 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 27 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Feb 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 13 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 30 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 27 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 13 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 30 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
